Clinical trials: Influenza Vaccines
Influenza, Influenza Vaccines
Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults
The present study is designed to assess the lot-to-lot consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza candidate vaccine (GSK1562902A) in adults aged between 18 and 60 years.
- Trial name
- NCT00449670
- Testing
- H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain), H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain), H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)
- Where
- 6 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human, SARS-CoV-2 Infection
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the…
- Conditions
- Influenza, Human, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT06237049
- Testing
- BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV
- Where
- 30 sites in United States
- Volunteers
- 644 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00968526
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- Belgium
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, Influenza A
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the…
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT05354115
- Testing
- Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
- Where
- United States
- Volunteers
- 676 people
- Sponsor
- Abbott Rapid Dx
Influenza
Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults
A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine (recombinant) in Healthy Adults.
- Trial name
- NCT00754455
- Testing
- Influenza VLP Vaccine (recombinant)
- Where
- 4 sites in United States
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza Virus
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to <72 Months of Age.
- Trial name
- NCT01964989
- Testing
- Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
- Where
- 167 sites in United States, Canada and 9 more
- Volunteers
- 10,644 people, healthy volunteers welcome
- Sponsor
- Seqirus
Randomized
To Explore a Bridging Index for the Effectiveness of the Clinical Trial
To explore a bridging index for the effectiveness of the clinical trial with Nasal Spray Lyophilized Live Attenuated Influenza Vaccine
- Trial name
- NCT04825340
- Testing
- Nasal Spray Lyophilized Live Attenuated Influenza Vaccine
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Influenza
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.
- Trial name
- NCT05523089
- Testing
- CD388
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Respiratory Viral Infections, Influenza
Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections
A multicenter double-blinded, randomized, placebo-controlled, parallel-group comparative Phase II clinical study to assess safety, tolerability, efficacy and optimal dose of XC221 vs.
- Trial name
- NCT03455491
- Testing
- XC221 100 mg, XC221 200 mg
- Where
- 11 sites in Russia
- Volunteers
- 120 people
- Sponsor
- PHARMENTERPRISES LLC
Influenza
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
The hypothesis for this trial is that the incidence of a pre-defined composite of common systemic hypersensitivity adverse events for Flublok recipients is non-inferior to that reported for licensed IIV recipients.
- Trial name
- NCT01825200
- Testing
- Flublok, Afluria
- Where
- 14 sites in United States
- Volunteers
- 2,640 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Severe Sepsis
Symphony IL-6 Study in Patients at Risk of Severe Sepsis
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05665153
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bluejay Diagnostics, Inc.
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02831751
- Testing
- 30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain)
- Where
- 15 sites in United States, Canada
- Volunteers
- 1,001 people, healthy volunteers welcome
- Sponsor
- Medicago
H7N9 Influenza Vaccine
A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects
This study aims to evaluate the safety and immunogenicity of an inactivated cell culture derived H7N9 vaccine in healthy adult subjects.
- Trial name
- NCT02436928
- Testing
- AT-501 High Dose vaccine, AT-501 High Dose vaccine with Adjuvant, AT-501 Low Dose vaccine
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Immunization, Human Influenza
Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization
The purpose of this study is to determine whether Yili Lactoferrin ShuHua Milk are effective in reducing the occurrence of flu symptoms.
- Conditions
- Immunization, Human Influenza, Common Cold
- Trial name
- NCT01677702
- Testing
- Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml), Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml), Recombined low protein milk
- Where
- 2 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Inner Mongolia Yili Industrial Group Co., Ltd
Influenza
Immunogenicity and Safety of GSK Biologicals' FluLaval® TF
The present study is intended to assess a novel formulation of FluLaval. The idea is to obtain preliminary data on the safety and immune response to the FluLaval TF influenza vaccine in adults.
- Trial name
- NCT00727428
- Testing
- FluLaval® TF
- Where
- Belgium
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic Influenza
A/H5N1 Dose Ranging Study With Adjuvant Patch
This is a Phase 1/2, randomized, observer-blind, placebo-controlled clinical trial. A maximum of 500 eligible subjects in 10 groups will be enrolled, randomized and vaccinated in this study.
- Trial name
- NCT00532792
- Testing
- A/H5N1
- Where
- 5 sites in United States
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Human Influenza
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
To evaluate the safety of a single intramuscular (IM) injection of trivalent nonadjuvated influenza study vaccine, formulation 2012/2013, in adult and elderly subjects and the antibody response to each influenza vaccine antigen…
- Trial name
- NCT01636102
- Testing
- Trivalent influenza virus vaccine (TIV)
- Where
- Belgium
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Infections, Meningococcal
Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults
The purpose of this study is to demonstrate, in 18-55 year old adults, the consistency of different manufactured lots of meningococcal vaccine GSK134612, the non-inferiority of GSK134612 compared to licensed meningococcal vaccine…
- Trial name
- NCT00453986
- Testing
- Meningococcal vaccine GSK134612, Mencevax™ACWY, Fluarix™
- Where
- 4 sites in Lebanon, Philippines
- Volunteers
- 1,352 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prevention of Influenza
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
- Trial name
- NCT07133802
- Testing
- Test Group
- Volunteers
- 6,680 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.